{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:32:26Z","timestamp":1789021946551,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"MPS1 Foundation"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UL1TR000124"],"award-info":[{"award-number":["UL1TR000124"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ymgmr.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,1,15]],"date-time":"2017-01-15T05:45:19Z","timestamp":1484459119000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II"],"prefix":"10.1016","volume":"10","author":[{"given":"Lynda E.","family":"Polgreen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Kunin-Batson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Rudser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-8305","authenticated-orcid":false,"given":"Richard K.","family":"Vehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine J.","family":"Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2017.01.002_bb0005","doi-asserted-by":"crossref","unstructured":"E.B. Fung, J.A. Johnson, J. Madden, T. Kim, P. Harmatz, Bone density assessment in patients with mucopolysaccharidosis: a preliminary report from patients with MPS II and VI, J. Pediatr. Rehabil. Med. 3 (n.d.) 13\u201323.","DOI":"10.3233\/PRM-2010-0105"},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/bmt.2008.20","article-title":"Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation","volume":"41","author":"Polgreen","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0015","doi-asserted-by":"crossref","unstructured":"E. Oussoren, M.M. Brands, G.J. Ruijter, A.T. der Ploeg, A.J. Reuser, Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options, Biochim. Biophys. Acta 1812 (n.d.) 1542\u201356.","DOI":"10.1016\/j.bbadis.2011.07.013"},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01241398-200401000-00019","article-title":"Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation","volume":"24","author":"Weisstein","year":"2004","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0025","article-title":"Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey","volume":"2","author":"Link","year":"2010","journal-title":"Orthop. Rev. Pavia."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","article-title":"The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS)","volume":"109","author":"Jones","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S8756-3282(01)00679-2","article-title":"Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease","volume":"30","author":"Monroy","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0040","first-page":"137","article-title":"Chondro-osseous pathology in the chondrodystrophies","author":"Rimoin","year":"1976","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s002239900656","article-title":"Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI","volume":"65","author":"Nuttall","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-0004.1998.tb02745.x","article-title":"Murine MPS I: insights into the pathogenesis of Hurler syndrome","volume":"53","author":"Russell","year":"1998","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0055","first-page":"305","article-title":"Hurler syndrome with special reference to histologic abnormalities of the growth plate","author":"Silveri","year":"1991","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000156510.96253.5A","article-title":"Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models","volume":"57","author":"Simonaro","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"Involvement of the Toll-like receptor 4 pathway and use of TNF-\u03b1 antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/labinvest.3780345","article-title":"Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses","volume":"81","author":"Simonaro","year":"2001","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022447","article-title":"Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI","volume":"6","author":"Eliyahu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/iep.12033","article-title":"Characterization of joint disease in mucopolysaccharidosis type I mice","volume":"94","author":"de Oliveira","year":"2013","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2353\/ajpath.2008.070564","article-title":"Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases","volume":"172","author":"Simonaro","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0090","first-page":"85","article-title":"Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation","volume":"3","author":"Simonaro","year":"2010","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0095","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/hmg\/ddn088","article-title":"A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis","volume":"17","author":"Martin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ymgme.2016.01.012","article-title":"Elevated TNF-\u03b1 is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI","volume":"117","author":"Polgreen","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0105","first-page":"39","article-title":"Preventing joint damage as the best measure of biologic drug therapy","volume":"65","author":"Bresnihan","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000289200","article-title":"T cells as sources and targets of TNF: implications for immunity and autoimmunity","volume":"11","author":"Chatzidakis","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0115","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U","volume":"43","author":"Tugwell","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0125","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0130","first-page":"465","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0470-7","article-title":"Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation","volume":"11","author":"Schmidt","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2017.01.002_bb0165","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"den Broeder","year":"2002","journal-title":"J. Rheumatol."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426916300921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426916300921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:49:43Z","timestamp":1762001383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426916300921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":33,"alternative-id":["S2214426916300921"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2017.01.002","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}